Dec 16, 2024 · Last year, we documented nine biotechs we thought you should watch in 2024. Now, as the year has flown by and the end of 2024 is approaching, biotech companies will be setting out their plans for next year as they continue to work towards bringing their innovative therapies through the clinic and to the market in an attempt to bring new and groundbreaking medicines to patients suffering from ...

Jan 25, 2024 · AI reshaping biotech: A key trend for 2024. AI has completely shifted the paradigm in the biotech industry. The past year has seen a gold rush in AI applications for the biopharma sector, for drug and protein discovery, or even treatment repurposing.

Visit our 2025 biotech funding tracker for the newest funding rounds!. Discover the latest in biotech funding on our dedicated page. We meticulously curate and categorize significant fundraising events to keep you informed about the cutting-edge trends and investments driving the industry forward.

January 2025:. 22-23 January 2025: Paris, France – Pharmapack 28-30 January 2025: Frankfurt, Germany – mRNA-based Therapeutics Summit 29-30 January 2025: London, UK – Festival of Genomics and Biodata; February 2025: 4 February 2025: Zurich, Switzerland – Zurich Life Science Day 2025; 6-8 February 2025: Strasbourg, France – 7th European CAR T-cell Meeting

Jan 2, 2025 · GSK goes big in December 2024 with licensing deals. Among GSK’s latest conquests is nabbing the licensing rights to DB-1324, an antibody-drug conjugate (ADC) from Chinese biotech Duality Biologics.

Oct 9, 2024 · FDA approves two new COPD treatments in 2024 Verona Pharma’s Ohtuvayre. In June 2024, the FDA approved the first inhaled product with a novel mechanism of action available for the maintenance treatment of COPD in more than 20 years. The product, called Ohtuvayre (ensifentrine), was developed by Verona Pharma – a London-based company established 19 years ago to unlock the potential of ...

January 2024: AbbVie and Umoja Biopharma, both based in the United States, are partnering to develop novel in-situ CAR-T cell therapies. Umoja is eligible to receive up to $1.44 billion for option exercise fees, development, and regulatory milestones.

Mar 12, 2024 · Akouos. Akouos, founded in 2016 focuses on developing gene therapies for hearing loss.The Boston-based biotech company uses adeno-associated viral (AAV) vector-based gene therapy techniques aimed at restoring and preserving hearing across a variety of conditions, from genetic mutations to aging-related hearing loss .

Dec 19, 2023 · 2024 is shaping up to be an exciting year for the industry. Discover nine biotech companies to keep an eye on in 2024.

Biotech associations play a crucial role in advancing the industry by connecting biotech companies, pharmaceutical firms, academic institutions, research organizations, policymakers, and investors.